Palatin Announces Presentation at the 2022 Crohn’s and Colitis Congress
Pre-clinical data demonstrate positive treatment effects of melanocortins for ulcerative colitis Genomic data characterizing the mechanism of action Jan 21, 2022, 07:30 ET CRANBURY, N.J., Jan. 21, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, …
Palatin Announces Presentation at the 2022 Crohn’s and Colitis Congress Read More »